Understanding Patient Preferences for the Treatment of Lupus Nephritis With Adaptive Conjoint Analysis

Background.Incorporation of patient preferences into treatment decisions is an essential component of medical care. Conjoint analysis is an established method of eliciting consumer preferences in market research and is being increasingly used to study patient preferences for health care. Objective.To examine the value of Adaptive Conjoint Analysis (ACA), a unique method of performing conjoint analysis, and to evaluate patient treatment preferences. Research Design. Interactive computer survey. Subjects.Consecutive women (n = 103) with lupus followed in three community rheumatology practices. Measures.ACA was used to assess patients’ relative preferences for specific cytotoxic medication characteristics, and to estimate the percentage of women preferring cyclophosphamide over azathioprine for different risk-benefit scenarios. Results.All participants were able to complete the conjoint task in 14 ±5 minutes. Of the nine medication characteristics studied, efficacy and risk for infection had the greatest impact on preference (each accounting for 20% of the variation in preferences), suggesting that patients consider differences in the risk for infection equally as important as differences in the probability of renal survival. Premenopausal women wanting more children were less likely to choose cyclophosphamide compared with their counterparts (56% vs. 80%, P = 0.04). Modest changes in the probability of renal survival or risk for major toxicity lowered the percentage of women preferring cyclophosphamide by more than 20%, irrespective of their desire for more children. Conclusions.ACA is a feasible method of assessing how patients consider specific medication characteristics and predicting treatment preferences under different risk-benefit scenarios. ACA may be a valuable tool to incorporate patient preferences into medical decision-making.

[1]  A. Scott,et al.  Agency in health care. Examining patients' preferences for attributes of the doctor-patient relationship. , 1998, Journal of health economics.

[2]  E. Speedling,et al.  Building an effective doctor-patient relationship: from patient satisfaction to patient participation. , 1985, Social science & medicine.

[3]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[4]  A Calin,et al.  Willingness to accept risk in the treatment of rheumatic disease. , 1990, Journal of epidemiology and community health.

[5]  A. Steinberg,et al.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.

[6]  P. Casali,et al.  Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. , 2000, Arthritis and rheumatism.

[7]  J. Sloan,et al.  Decision making during serious illness: what role do patients really want to play? , 1992, Journal of clinical epidemiology.

[8]  J. Concato,et al.  Unwillingness of rheumatoid arthritis patients to risk adverse effects. , 2002, Rheumatology.

[9]  D H Hickam,et al.  The Effect of Physicians' Explanations on Patients' Treatment Preferences , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  A. Steinberg,et al.  NIH conference. Lupus nephritis. , 1987, Annals of internal medicine.

[11]  Chan Su Park,et al.  Surprising Robustness of the Self-Explicated Approach to Customer Preference Structure Measurement , 1997 .

[12]  John E. Ware,et al.  Expanding Patient Involvement in Care , 1985 .

[13]  Deb Feldman-Stewart,et al.  What Questions Do Patients with Curable Prostate Cancer Want Answered? , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  Dick R. Wittink,et al.  Note---Conjoint Reliability Measures , 1989 .

[15]  J. Cameron,et al.  Lupus Nephritis , 1959, Clinics in rheumatic diseases.

[16]  B. Fischhoff,et al.  Rating the Risks , 1979 .

[17]  M. Ward.  Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. , 2000, Archives of internal medicine.

[18]  V. Wright,et al.  What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? , 1990, British journal of rheumatology.

[19]  D. Mazur,et al.  What should patients be told prior to a medical procedure? Ethical and legal perspectives on medical informed consent. , 1986, The American journal of medicine.

[20]  H. Llewellyn-Thomas,et al.  Presenting clinical trial information: a comparison of methods. , 1995, Patient education and counseling.

[21]  J. Benbassat,et al.  Patients' preferences for participation in clinical decision making: a review of published surveys. , 1998, Behavioral medicine.

[22]  D. Felson,et al.  Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. , 1984, The New England journal of medicine.

[23]  D. Mazur.  Informed consent: court viewpoints and medical decision making. , 1986, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  D. Boumpas,et al.  Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy , 1993, Annals of Internal Medicine.

[25]  C L Kaufmann,et al.  Informed consent and patient decision making: two decades of research. , 1983, Social science & medicine.

[26]  H A Llewellyn-Thomas,et al.  The assessment of values in laryngeal cancer: reliability of measurement methods. , 1984, Journal of chronic diseases.

[27]  A. Ash,et al.  Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients. , 1989, Journal of general internal medicine.

[28]  D M Trandel-Korenchuk,et al.  Patient participation in decision making. , 1982, The Nurse practitioner.

[29]  D H Hickam,et al.  Patients’ interpretations of probability terms , 1991, Journal of general internal medicine.

[30]  Peter Wright.  Consumer Choice Strategies: Simplifying Vs. Optimizing , 1975 .

[31]  Studying patients' preferences in health care decision making. Health Services Research Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[32]  Angela Coulter,et al.  Paternalism or partnership? , 1999, BMJ.

[33]  T. Pullar,et al.  The risk of treatment. A study of rheumatoid arthritis patients' attitudes. , 1998, British journal of rheumatology.

[34]  F. Houssiau,et al.  Side-effects of intravenous cyclophosphamide pulse therapy , 1997, Lupus.

[35]  D Feldman-Stewart,et al.  Using a Treatment-tradeoff Method to Elicit Preferences for the Treatment of Locally Advanced Non-Small-cell Lung Cancer , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  L. Daltroy,et al.  Doctor-patient communication in rheumatological disorders. , 1993, Bailliere's clinical rheumatology.

[37]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[38]  J. Concato,et al.  Preference for disclosure of information among patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[39]  Philippe Cattin,et al.  Commercial Use of Conjoint Analysis: An Update , 1989 .

[40]  H. Llewellyn-Thomas,et al.  Health State Descriptions Purposes, Issues, A Proposal , 1996, Medical care.

[41]  M Ryan,et al.  Using conjoint analysis to assess women's preferences for miscarriage management. , 1997, Health economics.

[42]  A. Scott,et al.  Patients, Doctors and Contracts: An Application of Principal-Agent Theory to the Doctor-Patient Relationship , 1999 .

[43]  A. Ciampi,et al.  The longterm prognosis of lupus nephritis: the impact of disease activity. , 1993, Journal of Rheumatology.

[44]  J F Jekel,et al.  Perils, pitfalls, and possibilities in talking about medical risk. , 1999, JAMA.

[45]  Court Viewpoints and Medical Decision Making , 1986 .

[46]  I. Vertinsky,et al.  Measuring consumer desire for participation in clinical decision making. , 1974, Health services research.

[47]  J. Fries,et al.  A toxicity index for comparison of side effects among different drugs. , 1990, Arthritis and rheumatism.

[48]  Paul E. Green,et al.  Conjoint Analysis in Marketing: New Developments with Implications for Research and Practice , 1990 .

[49]  Jagdip Singh,et al.  Medical decision-making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. , 1998, Medical care.

[50]  M Ryan,et al.  Using conjoint analysis to elicit preferences for health care , 2000, BMJ : British Medical Journal.

[51]  A. Steinberg,et al.  Studies of immunosuppressive drugs in the treatment of lupus nephritis. , 1987, Rheumatic diseases clinics of North America.

[52]  S. Kaplan,et al.  Expanding patient involvement in care. Effects on patient outcomes. , 1985, Annals of internal medicine.